PL375078A1 - Benzoic acid derivatives as modulators of ppar alpha and gamma - Google Patents

Benzoic acid derivatives as modulators of ppar alpha and gamma

Info

Publication number
PL375078A1
PL375078A1 PL03375078A PL37507803A PL375078A1 PL 375078 A1 PL375078 A1 PL 375078A1 PL 03375078 A PL03375078 A PL 03375078A PL 37507803 A PL37507803 A PL 37507803A PL 375078 A1 PL375078 A1 PL 375078A1
Authority
PL
Poland
Prior art keywords
modulators
gamma
benzoic acid
acid derivatives
ppar alpha
Prior art date
Application number
PL03375078A
Other languages
English (en)
Polish (pl)
Inventor
Lanna Li
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL375078A1 publication Critical patent/PL375078A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PL03375078A 2002-06-20 2003-06-17 Benzoic acid derivatives as modulators of ppar alpha and gamma PL375078A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201937A SE0201937D0 (sv) 2002-06-20 2002-06-20 Therapeutic agents

Publications (1)

Publication Number Publication Date
PL375078A1 true PL375078A1 (en) 2005-11-14

Family

ID=20288295

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03375078A PL375078A1 (en) 2002-06-20 2003-06-17 Benzoic acid derivatives as modulators of ppar alpha and gamma

Country Status (21)

Country Link
US (1) US7521461B2 (is)
EP (1) EP1517680A1 (is)
JP (1) JP4327085B2 (is)
KR (1) KR20050014014A (is)
CN (1) CN100400512C (is)
AR (1) AR040332A1 (is)
AU (1) AU2003240101B2 (is)
BR (1) BR0311840A (is)
CA (1) CA2490687A1 (is)
IL (1) IL165672A0 (is)
IS (1) IS7639A (is)
MX (1) MXPA04012694A (is)
NO (1) NO20045222L (is)
NZ (1) NZ536972A (is)
PL (1) PL375078A1 (is)
RU (1) RU2339613C2 (is)
SE (1) SE0201937D0 (is)
TW (1) TW200403209A (is)
UA (1) UA77527C2 (is)
WO (1) WO2004000295A1 (is)
ZA (1) ZA200409690B (is)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
WO2004000790A1 (en) * 2002-06-20 2003-12-31 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
US7351858B2 (en) 2002-06-20 2008-04-01 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
WO2005026134A1 (en) * 2003-09-17 2005-03-24 Novartis Ag Organic compounds
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
KR101478933B1 (ko) * 2004-12-28 2015-01-02 키넥스 파마슈티컬즈, 엘엘씨 세포 증식 질환의 치료를 위한 조성물 및 방법
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
US7816405B2 (en) * 2005-04-19 2010-10-19 Eisai R&D Management Co., Ltd. Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
JP2009507846A (ja) * 2005-09-07 2009-02-26 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
JP2007234800A (ja) 2006-02-28 2007-09-13 Tdk Corp 電子部品及びその製造方法
RU2456265C2 (ru) * 2006-03-31 2012-07-20 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Биологически доступная для перорального применения кофейная кислота, относящаяся к противоопухолевым лекарственным средствам
JP5564251B2 (ja) * 2006-06-29 2014-07-30 キネックス ファーマシューティカルズ， エルエルシー キナーゼカスケードを調節するためのビアリール組成物および方法
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP3053440B1 (en) 2007-04-11 2020-08-12 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
CN102905700A (zh) 2010-04-16 2013-01-30 金克斯医药品有限公司 用于预防和治疗癌症的组合物以及方法
WO2013019621A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
CN109999040A (zh) 2012-08-30 2019-07-12 阿西纳斯公司 蛋白质酪氨酸激酶调节剂
KR102603436B1 (ko) * 2017-11-30 2023-11-16 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 방향족 화합물, 약학적 조성물 및 그 용도
JP2023546996A (ja) * 2020-10-23 2023-11-08 ニンバス クロソー， インコーポレイテッド Ｃｔｐｓ１阻害剤およびその使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2517229A1 (de) * 1975-04-18 1976-10-28 Boehringer Mannheim Gmbh Phenylalkylcarbonsaeure-derivate und verfahren zu ihrer herstellung
DK148576A (da) * 1975-04-18 1976-10-19 Boehringer Mannheim Gmbh Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling
US5334753A (en) * 1992-03-12 1994-08-02 Rhone-Poulenc Agriculture Ltd Processes for preparing ortho-substituted benzoic acids
DE19615263A1 (de) 1996-04-18 1997-10-23 Bayer Ag Benzyloxy-substituierte Phenylglycinolamide
DE19616948C1 (de) 1996-04-27 1997-11-27 Wagner Gmbh J Schneidwerkzeug, insbesondere Astschere
JPH1072371A (ja) 1996-08-28 1998-03-17 Sankyo Co Ltd 回腸型胆汁酸トランスポーター阻害剤
US5922767A (en) * 1996-10-30 1999-07-13 Ss Pharmaceutical Co., Ltd. Substituted benzylurea derivatives and medicine containing the same
CN1302206A (zh) * 1997-10-17 2001-07-04 阿温蒂斯药物制品公司 喹啉衍生物的治疗用途
NZ503809A (en) 1997-12-19 2002-04-26 Schering Ag Ortho-anthranilamide derivatives as anti-coagulants
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
DE19825804C2 (de) 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
SK15532001A3 (sk) 1999-04-28 2002-06-04 Aventis Pharma Deutschland Gmbh Deriváty kyselín s dvoma arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú
PT1177176E (pt) 1999-04-28 2006-08-31 Aventis Pharma Gmbh Derivados de acidos triarilicos como ligandos de receptores ppar.
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
GB9919411D0 (en) * 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
US6509374B2 (en) * 2000-04-17 2003-01-21 Novo Nordisk A/S Compounds, their preparation and use
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
WO2004000295A1 (en) 2003-12-31
CN1662230A (zh) 2005-08-31
AR040332A1 (es) 2005-03-30
EP1517680A1 (en) 2005-03-30
NO20045222L (no) 2005-01-19
TW200403209A (en) 2004-03-01
RU2004135542A (ru) 2005-08-10
ZA200409690B (en) 2005-10-11
MXPA04012694A (es) 2005-03-23
SE0201937D0 (sv) 2002-06-20
US20050267149A1 (en) 2005-12-01
IL165672A0 (en) 2006-01-15
RU2339613C2 (ru) 2008-11-27
BR0311840A (pt) 2005-03-15
IS7639A (is) 2005-01-12
CA2490687A1 (en) 2003-12-31
JP2006502105A (ja) 2006-01-19
UA77527C2 (en) 2006-12-15
KR20050014014A (ko) 2005-02-05
AU2003240101A1 (en) 2004-01-06
JP4327085B2 (ja) 2009-09-09
AU2003240101B2 (en) 2006-09-21
CN100400512C (zh) 2008-07-09
NZ536972A (en) 2006-06-30
US7521461B2 (en) 2009-04-21

Similar Documents

Publication Publication Date Title
PL375078A1 (en) Benzoic acid derivatives as modulators of ppar alpha and gamma
NO20035086D0 (no) Karboksylsyresubstituerte oxazolderivater for anvendelse som PPAR-alfa og gamma-aktivatorer i behandling av diabetes
PL375877A1 (en) Hydantoine derivatives and their use as tace inhibitors
AU2003288902A8 (en) Microcapsules and methods of use
EP1465615A4 (en) TRICYCLIC BISENONE DERIVATIVES AND METHODS OF USE
AP2004003110A0 (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
DK1501815T3 (da) Substituerede phenylacetamider og anvendelse deraf som glucokinaseaktivatorer
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
AU2003278832A8 (en) Optical biosensors and methods of use thereof
SI2025670T1 (sl) Uporaba derivatov 3-feniltio-1H-indol-1-ocetne kisline kot modulatorjev aktivnosti CRTh2 receptorja
NO20041872L (no) Esterforbindelser og medisinsk anvendelse derav
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
EP1556347A4 (en) GAMMA LACTAME AS PROSTAGLAND INAGONISTS AND THEIR USE
AU2003259717A8 (en) Modulators of rabggt and methods of use thereof
PL377696A1 (pl) Enancjomery pochodnych kwasu tiofenohydroksamowego i ich zastosowanie jako inhibitorów HDAC
EP1691845A4 (en) COMPOUNDS WITH MATRIX METALOPROTEINASE SUBSTRATES AND METHOD OF USE THEREOF
EP1499186A4 (en) USE OF HEM-OXYGENASE-1 AND HEM-DEGRADABLE PRODUCTS
EP1487776A4 (en) ACID COMPOUNDS AND ESTERS AND METHODS OF USE THEREOF
AU2003278157A1 (en) Novel phenylethanolamine derivatives and the use of the same as beta-3-agonists
DK1537091T3 (da) Hidtil ukendte 2-arylthiazolforbindelser som PPAR alpha- og PPAR gamma-agonister
DK1551814T3 (da) Chirale oxazol-arylpropionsyrederivater og anvendelse deraf som ppar-agnister
AU2003258942A1 (en) Imidazolidinedione-derivatives and their use as metalloproteinase inhibitors
AU2003221960A1 (en) Indane acetic acid derivatives and their use as pharmaceutical agents
AU2003203003A8 (en) Sign and awning attachment system and method of use
AU2003218715A8 (en) Azepane derivatives and their use as atk1 inhibitors

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)